We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Combined Automated Blood Tests Estimate Prostate Cancer Probability

By LabMedica International staff writers
Posted on 19 Apr 2010
Three automated blood tests combined into one index estimates a man's probability of having prostate cancer found on biopsy.

A new prostate disease marker, p2prostate-specific antigen (p2PSA), and the Prostate Health Index (phi), significantly improve the specificity of prostate cancer biomarker assessment. More...


Serum Beckman Coulter (Nyon, Switzerland) phi is a multivariate index incorporating prostate-specific antigen (PSA), free PSA, and proPSA concentrations into a single result. This enables medical professionals to estimate the probability of cancer in men aged 50 and older with total PSA in the 2.0-10.0 ng/mL range and a nonsuspicious digital rectal examination (DRE).

proPSA is a novel serum marker strongly associated with prostate cancer and delivers added specificity to PSA. As a result, phi contributes to reduce significantly the number of negative biopsies resulting from suspicious PSA or free PSA results.

Beckman Coulter phi is a composite score of Access Hybritech PSA, free PSA and the new p2PSA assay, which measures the isoform proPSA.

A new website introduced by Beckman Coulter, was designed to encourage dialogue between patients, physicians, and laboratory professionals. It provides guidance and education to all parties in order to foster confident prostate biopsy decision-making. The website (please see related links below) provides links to credible medical resources, the latest unbiased scientific studies, and details the benefits of the latest blood test, which can noninvasively identify patients who are most likely to have a negative prostate biopsy.

Related Links:

Beckman Coulter

Prostate Health Index



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.